2024
Mass incarceration as a driver of the tuberculosis epidemic in Latin America and projected effects of policy alternatives: a mathematical modelling study
Liu Y, Mabene Y, Camelo S, Rueda Z, Pelissari D, Johansen F, Huaman M, Avalos-Cruz T, Alarcón V, Ladutke L, Bergman M, Cohen T, Goldhaber-Fiebert J, Croda J, Andrews J. Mass incarceration as a driver of the tuberculosis epidemic in Latin America and projected effects of policy alternatives: a mathematical modelling study. The Lancet Public Health 2024, 9: e841-e851. PMID: 39419058, PMCID: PMC11602220, DOI: 10.1016/s2468-2667(24)00192-0.Peer-Reviewed Original ResearchConceptsLatin AmericaIncarceration policiesIncarcerated populationsEffects of policy alternativesDuration of incarcerationMinistry of JusticePrison admissionsIncarceration ratesMass incarcerationIncarcerationPolicy alternativesInternational health agenciesEl SalvadorHistorical riseTuberculosis incidenceLatinPrisonAge structureHealth agenciesCounterfactual scenariosCountriesPolicyHealth crisisNational Tuberculosis ProgrammeTuberculosis epidemicThe greatest Dengue epidemic in Brazil: Surveillance, Prevention, and Control
Gurgel-Gonçalves R, de Oliveira W, Croda J. The greatest Dengue epidemic in Brazil: Surveillance, Prevention, and Control. Revista Da Sociedade Brasileira De Medicina Tropical 2024, 57: e00203-2024. PMID: 39319953, PMCID: PMC11415067, DOI: 10.1590/0037-8682-0113-2024.Peer-Reviewed Original ResearchConceptsHealth education initiativesPhase 3 clinical trialsPublic health systemMinistry of HealthIndoor residual sprayingSterile insect techniqueHealth servicesHealth systemTakeda vaccineCommunity mobilizationMultisectoral approachDengue epidemicsDengue casesEducational initiativesDengue mortalityResidual sprayingMosquito controlHome cleaningInsect techniqueAedes aegyptiPotential mosquito breeding sitesHealthVaccination coverageDengue virusVaccineAntecedent and persistent symptoms in COVID-19 and other respiratory illnesses: Insights from prospectively collected data in the BRACE trial
ald E, Pittet L, Barry S, Bonten M, Campbell J, Croda J, Croda M, Dalcolmo M, Davidson A, de Almeida e Val F, dos Santos G, Gardiner K, Gell G, Gwee A, Krastev A, Lacerda M, Lucas M, Lynn D, Manning L, McPhate N, Perrett K, Post J, Prat-Aymerich C, Quinn L, Richmond P, Wood N, Messina N, Curtis N, Group T. Antecedent and persistent symptoms in COVID-19 and other respiratory illnesses: Insights from prospectively collected data in the BRACE trial. Journal Of Infection 2024, 89: 106267. PMID: 39245151, PMCID: PMC11489119, DOI: 10.1016/j.jinf.2024.106267.Peer-Reviewed Original ResearchConceptsBraced trialsChronic respiratory diseasesHealthcare workersPre-existing symptomsRisk of PaCMulticentre randomised controlled trialNon-COVID-19Non-COVID-19 respiratory illnessesRandomised controlled trialsRespiratory illnessNon-COVID-19 illnessesSymptom patternsLonger-lasting symptomsProportion of COVID-19 casesRespiratory diseaseIllness episodesWHO definitionCOVID-19Compare symptomsControlled trialsRespiratory illness episodesSymptom dataPersistence of symptomsIllnessIncreased riskBCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial
Messina N, Pittet L, McDonald E, Moore C, Barry S, Bonten M, Byrne A, Campbell J, Croda J, Croda M, Dalcolmo M, de Almeida e Val F, de Oliveira R, dos Santos G, Douglas M, Gardiner K, Gwee A, Jardim B, Kollmann T, Lacerda M, Lucas M, Lynn D, Manning L, Marshall H, O’Connell A, Perrett K, Post J, Prat-Aymerich C, Rocha J, Rodriguez-Baño J, Wadia U, Warris A, Davidson A, Curtis N, Group T. BCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial. Journal Of Infection 2024, 89: 106245. PMID: 39127450, PMCID: PMC11409612, DOI: 10.1016/j.jinf.2024.106245.Peer-Reviewed Original ResearchConceptsBacille Calmette-GuerinBreakthrough COVID-19Healthcare workersSevere COVID-19Risk of severe COVID-19Placebo groupSymptomatic COVID-19BCG-DenmarkRisk of symptomatic COVID-19International randomised controlled trialRandomised controlled trialsBacille Calmette-Guerin vaccineVaccination of healthcare workersHealthcare centresSARS-CoV-2 testingAsymptomatic SARS-CoV-2 infectionRandomised 1:1SARS-CoV-2 infectionCOVID-19MITT populationControlled trialsHealthcareIntradermal doseModified intentionImmunomodulatory effectsInsights into SARS-CoV-2 Surveillance among Prison Populations in Mato Grosso do Sul, Brazil, in 2022
da Silva L, Alcantara L, Fonseca V, Frias D, Zardin M, de Castro Lichs G, Esposito A, Xavier J, Fritsch H, Lima M, de Oliveira C, de Arruda L, de Mello Almeida Maziero L, Barretos E, Oshiro P, Menezes E, de Freitas Cardoso L, Lemos E, Lourenço J, de Albuquerque C, do Carmo Said R, Rosewell A, Demarchi L, Croda J, Giovanetti M, Gonçalves C. Insights into SARS-CoV-2 Surveillance among Prison Populations in Mato Grosso do Sul, Brazil, in 2022. Viruses 2024, 16: 1143. PMID: 39066305, PMCID: PMC11281713, DOI: 10.3390/v16071143.Peer-Reviewed Original ResearchConceptsNext-generation sequencingPrison populationIncarcerated populationsOvercrowded cellsGenome sequenceGenomic characteristicsPrisonGenomic surveillanceEnclosed populationMato GrossoAverage coverageIsolation protocolSARS-CoV-2RT-qPCR testSARS-CoV-2 surveillanceRT-qPCRSequenceFrequent transferEpidemiological monitoringLimited healthcare accessGenomeCellsOmicron variantSeroprevalence of Treponema pallidum infection among high-risk populations from Brazil
Queiroz J, Barbosa M, Perez E, da Silva B, de Souza G, Gonçalves C, Croda J, Simionatto S. Seroprevalence of Treponema pallidum infection among high-risk populations from Brazil. Acta Tropica 2024, 256: 107255. PMID: 38761835, DOI: 10.1016/j.actatropica.2024.107255.Peer-Reviewed Original ResearchConceptsSexually transmitted infectionsHigh-risk groupCases of syphilisFactors associated with syphilisPregnant womenHistory of sexually transmitted infectionsPublic health strategiesHealthy populationSignificant public health concernPrevent future complicationsHigh risk of infectionHigh-risk populationPublic health concernHealth strategiesParticipant demographicsCross-sectional oneRisk of infectionVulnerable populationsFuture complicationsPLHIVTreatment outcomesHealth concernHigh riskSyphilisInfectionFactors influencing adverse events following COVID-19 vaccination
Villanueva P, McDonald E, Croda J, Croda M, Dalcolmo M, dos Santos G, Jardim B, Lacerda M, Lynn D, Marshall H, Oliveira R, Rocha J, Sawka A, Val F, Pittet L, Messina N, Curtis N. Factors influencing adverse events following COVID-19 vaccination. Human Vaccines & Immunotherapeutics 2024, 20: 2323853. PMID: 38445666, PMCID: PMC10936640, DOI: 10.1080/21645515.2024.2323853.Peer-Reviewed Original ResearchConceptsVaccine typesSystemic reactionsIncidence of AEFIAdverse eventsVaccine doseIncidence of adverse eventsCovid-19 specific vaccineCOVID-19 vaccineNested cohort studyIgG antibody responsesRisk of AEFICOVID-19 vaccine typesChAdOx1 recipientsBNT162b2 recipientsCohort studyPfizer-BioNTechCoronaVac vaccineAntibody responseChAdOx1Oxford-AstraZenecaCoronaVacBNT162b2Local reactionsDoseDevelopment of COVID-19 vaccinesEffect of BCG vaccination against Mycobacterium tuberculosis infection in adult Brazilian health-care workers: a nested clinical trial
dos Santos P, Messina N, de Oliveira R, da Silva P, Puga M, Dalcolmo M, dos Santos G, de Lacerda M, Jardim B, de Almeida e Val F, Curtis N, Andrews J, Croda J. Effect of BCG vaccination against Mycobacterium tuberculosis infection in adult Brazilian health-care workers: a nested clinical trial. The Lancet Infectious Diseases 2024, 24: 594-601. PMID: 38423021, PMCID: PMC11111441, DOI: 10.1016/s1473-3099(23)00818-6.Peer-Reviewed Original ResearchConceptsQuantiFERON-TB GoldPlacebo groupEffect of BCG vaccinationBCG vaccinationBCG groupBCG-DenmarkHealth-care workersNegative baseline resultsMonths of treatmentMycobacterium tuberculosis infectionAdult pulmonary tuberculosisQuantiFERON-TBMedian ageRandomised controlled trialsPulmonary tuberculosisNo significant differenceEfficacy outcomesTuberculosis infectionClinical trialsControlled trialsEffect of vaccinationTreatment drugsTuberculosis preventionSubstudySignificant differenceIncarceration and TB: the epidemic beyond prison walls
Sequera G, Aguirre S, Estigarribia G, Walter K, Horna-Campos O, Liu Y, Andrews J, Croda J, Garcia-Basteiro A. Incarceration and TB: the epidemic beyond prison walls. BMJ Global Health 2024, 9: e014722. PMID: 38382977, PMCID: PMC10882329, DOI: 10.1136/bmjgh-2023-014722.Peer-Reviewed Original ResearchCatastrophic Floods in Rio Grande do Sul, Brazil: The Need for Public Health Responses to Potential Infectious Disease Outbreaks
Martins-Filho P, Croda J, Araújo A, Correia D, Quintans-Júnior L. Catastrophic Floods in Rio Grande do Sul, Brazil: The Need for Public Health Responses to Potential Infectious Disease Outbreaks. Revista Da Sociedade Brasileira De Medicina Tropical 2024, 57: e00603-2024. PMID: 38808800, PMCID: PMC11136508, DOI: 10.1590/0037-8682-0162-2024.Peer-Reviewed Original ResearchAdvances in the development of new vaccines for tuberculosis and Brazil’s role in the effort forward the end TB strategy
Junqueira-Kipnis A, de Cerqueira Leite L, Croda J, Chimara E, Carvalho A, Arcêncio R. Advances in the development of new vaccines for tuberculosis and Brazil’s role in the effort forward the end TB strategy. Memórias Do Instituto Oswaldo Cruz 2024, 119: e240093. PMID: 39383403, PMCID: PMC11452070, DOI: 10.1590/0074-02760240093.Peer-Reviewed Original ResearchThe impact of sputum quality on Xpert positivity in active case-finding for TB
Oliveira da Silva B, Salindri A, Gonçalves T, Cunha E, da Silva Santos A, dos Santos P, Lemes I, Silva D, da Silva Oliveira V, Croda J, de Oliveira R, Andrews J. The impact of sputum quality on Xpert positivity in active case-finding for TB. The International Journal Of Tuberculosis And Lung Disease 2024, 28: 29-36. PMID: 38178289, DOI: 10.5588/ijtld.23.0244.Peer-Reviewed Original ResearchConceptsSputum qualityXpert-positiveCase findingChest X-rayLog-binomial regressionCross-sectional analysisMass screening programmeActive case findingCurrent smokingParticipant characteristicsScreening programmeSymptom screeningStandardised questionnaireSpot sputum samplesBlood-stained sputumAbnormal chest radiographBinomial regressionCAD4TBSputum appearanceMucopurulent sputumXpert testingSputum samplesClinical characteristicsSalivary specimensChest radiographs
2023
Seroprevalence Of SARS-COV-2 infection in asymptomatic indigenous from the largest Brazilian periurban area
de Oliveira L, Dos Santos Barbosa M, Leite Torres A, Croda M, Oliveira da Silva B, Dos Santos P, Rossoni R, Machado L, Croda J, Maymone Gonçalves C, Marques M, da Silva Ferreira T, Sardi S, Campos G, de Almeida G, Alves Gomes M, Marchioro S, Simionatto S. Seroprevalence Of SARS-COV-2 infection in asymptomatic indigenous from the largest Brazilian periurban area. PLOS ONE 2023, 18: e0295211. PMID: 38134187, PMCID: PMC10745159, DOI: 10.1371/journal.pone.0295211.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayCoronaVac inactivated vaccinesSARS-CoV-2SARS-CoV-2 infectionEnzyme-linked immunosorbent assay methodMedian ageSARS-CoV-2 antibodiesSeroprevalence of SARS-CoV-2 antibodiesSeroprevalence of SARS-CoV-2Asymptomatic individualsRapid testSeropositivity rateBlood samplesEthnic groupsElevated seroprevalenceImmunosorbent assaySeroprevalence of SARS-CoV-2 infectionSARS-CoV-2 rapid testSeropositivityAntibodiesVulnerable ethnic groupsSeroprevalenceGenomic characterization of SARS-CoV-2 from an indigenous reserve in Mato Grosso do Sul, Brazil
de Oliveira L, de Rezende I, Navarini V, Marchioro S, Torres A, Croda J, Croda M, Gonçalves C, Xavier J, de Castro E, Lima M, Iani F, Adelino T, Aburjaile F, Demarchi L, Taira D, Zardin M, Fonseca V, Giovanetti M, Andrews J, Alcantara L, Simionatto S. Genomic characterization of SARS-CoV-2 from an indigenous reserve in Mato Grosso do Sul, Brazil. Frontiers In Public Health 2023, 11: 1195779. PMID: 37965526, PMCID: PMC10641392, DOI: 10.3389/fpubh.2023.1195779.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 lineagesIntroduction eventsCharacterization of SARS-CoV-2Nanopore sequencing platformSARS-CoV-2 positive samplesMultiple SARS-CoV-2 variantsMultiple introduction eventsPhylogenetic reconstructionPhylogenetic dataGenome sequenceSequencing platformsGenomic characterizationSARS-CoV-2Genomic surveillanceSARS-CoV-2 variantsLineagesMato GrossoMortality rateViral dynamicsIndigenous populationCo-circulationPrevalence of malesMidwestern BrazilPositive samplesIndigenous mobilizationPrioritizing persons deprived of liberty in global guidelines for tuberculosis preventive treatment
Narayan A, Salindri A, Keshavjee S, Muyoyeta M, Velen K, Rueda Z, Croda J, Charalambous S, García-Basteiro A, Shenoi S, Gonçalves C, da Silva L, Possuelo L, Aguirre S, Estigarribia G, Sequera G, Grandjean L, Telisinghe L, Herce M, Dockhorn F, Altice F, Andrews J. Prioritizing persons deprived of liberty in global guidelines for tuberculosis preventive treatment. PLOS Medicine 2023, 20: e1004288. PMID: 37788448, PMCID: PMC10547494, DOI: 10.1371/journal.pmed.1004288.Peer-Reviewed Original ResearchDengue Fever Surveillance in Mato Grosso do Sul: Insights from Genomic Analysis and Implications for Public Health Strategies
de Arruda L, Giovanetti M, Fonseca V, Zardin M, de Castro Lichs G, Asato S, Esposito A, Müller M, Xavier J, Fritsch H, Lima M, de Oliveira C, Santos E, de Mello Almeida Maziero L, Frias D, Neves D, da Silva L, Barretos E, Oshiro P, Goday B, dos Santos J, Kashima S, de Albuquerque C, do Carmo Said R, Rosewell A, Demarchi L, Croda J, Alcantara L, Gonçalves C. Dengue Fever Surveillance in Mato Grosso do Sul: Insights from Genomic Analysis and Implications for Public Health Strategies. Viruses 2023, 15: 1790. PMID: 37766197, PMCID: PMC10536684, DOI: 10.3390/v15091790.Peer-Reviewed Original ResearchConceptsInforming public health actionOn-site training programDiverse viral lineagesPublic health actionPublic health strategiesMultiple introduction eventsSecretary of HealthMonitoring viral evolutionHealth strategiesHealth actionsGenome sequenceGenomic analysisDynamics of dengue virusTraining programIntroduction eventsGenomic surveillanceViral transmission patternsViral lineagesPublic healthHealthMato GrossoEpidemiological dataViral evolutionPreventive measuresSurveillance activitiesPan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API)
Barbosa A, Chebabo A, Starling C, Pérez C, Cunha C, de Luna D, Nunes E, Zambrano G, Ferreira J, Croda J, Falavigna M, Gomes-da-Silva M, Thormann M, Cimerman S, Parahiba S, Tanni S, Bernardo W, Rodriguez-Morales A. Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API). Annals Of Clinical Microbiology And Antimicrobials 2023, 22: 67. PMID: 37550690, PMCID: PMC10408214, DOI: 10.1186/s12941-023-00623-w.Peer-Reviewed Original ResearchConceptsUse of hydroxychloroquineInfectious diseasesCOVID-19Treatment of outpatientsSARS-CoV-2/COVIDSevere COVID-19Evidence-based guidelinesPan American AssociationGuideline development processLack of benefitEvidence-based medicineAdverse eventsMechanical ventilationClinical manifestationsTherapeutic optionsPharmacological treatmentCOVID-19 episodeInpatient settingAmerican guidelinesGRADE systemSystematic reviewStrong recommendationsProphylaxisOutpatientsDiseaseMulticenter study of the natural history and therapeutic responses of patients with chikungunya, focusing on acute and chronic musculoskeletal manifestations – a study protocol from the clinical and applied research in Chikungunya (REPLICK network)
da Silva Duarte G, Jones A, de Goes Cavalcanti L, de Melo Rêgo M, Ribeiro G, Boyton R, Pereira D, Croda J, Costa F, Duarte A, Consolaro M, Stabeli R, Negrão F, Proenca-Modena J, Villalobos-Salcedo J, da Rocha Castelar Pinheiro G, de Barros Albuquerque A, de Almeida Barreto F, Moreira J, Ferrari I, Évora P, da Silva V, Lacerda M, Altmann D, Siqueira A. Multicenter study of the natural history and therapeutic responses of patients with chikungunya, focusing on acute and chronic musculoskeletal manifestations – a study protocol from the clinical and applied research in Chikungunya (REPLICK network). BMC Infectious Diseases 2023, 23: 499. PMID: 37507666, PMCID: PMC10386654, DOI: 10.1186/s12879-023-08292-y.Peer-Reviewed Original ResearchConceptsMusculoskeletal manifestationsStudy protocolTherapeutic responseChronic diseasesNatural historyDestructive disease courseMulticenter cohort studyLong-term sequelaeAssociated risk factorsClinical report formsClinical trial designQuality of lifeAliquots of bloodCohort studyCHIKV infectionDisease courseChronic painSymptomatic infectionBlood testsHigh morbidityMulticenter studyMusculoskeletal symptomsTherapeutic guidelinesClinical spectrumPatient cohortUnveiling the Impact of the Omicron Variant: Insights from Genomic Surveillance in Mato Grosso do Sul, Midwest Brazil
de Mello Almeida Maziero L, Giovanetti M, Fonseca V, Zardin M, de Castro Lichs G, de Rezende Romera G, Tsuha D, Frias D, Escandolhero V, Demarchi L, Castilho L, Barbosa K, Tebet D, Xavier J, Fritsch H, Lima M, de Oliveira C, Santos E, Kashima S, do Carmo Said R, Rosewell A, Croda J, Alcantara L, Gonçalves C. Unveiling the Impact of the Omicron Variant: Insights from Genomic Surveillance in Mato Grosso do Sul, Midwest Brazil. Viruses 2023, 15: 1604. PMID: 37515290, PMCID: PMC10386548, DOI: 10.3390/v15071604.Peer-Reviewed Original ResearchConceptsGenomic surveillanceWhole-genome sequencingMultiple introduction eventsGenome sequencePublic health interventionsGenomic dataGenomic monitoringIntroduction eventsPublic health responseGenomic landscapeDispersal dynamicsPhylodynamic analysesPublic health laboratoriesHealth interventionsMato GrossoHealth responseTransmissible variantsSignificant burdenCentral Public Health LaboratoryOmicron variantVariantsHealth laboratoriesSequenceMidwest region of BrazilViral strainsImpact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination
Messina N, Sperotto M, Puga M, da Silva P, de Oliveira R, Moore C, Pittet L, Jamieson T, Dalcolmo M, dos Santos G, Jardim B, Lacerda M, Curtis N, Croda J. Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination. Frontiers In Immunology 2023, 14: 1172851. PMID: 37465688, PMCID: PMC10352084, DOI: 10.3389/fimmu.2023.1172851.Peer-Reviewed Original ResearchConceptsRecent BCG vaccinationBCG vaccinationAntibody responseVaccine platformAnti-spike IgG responseCOVID-19 vaccinationCOVID-19 vaccineCoronaVac vaccinationPrior vaccinationVaccine responsesIgG responsesSecond doseIgG antibodiesHealthcare workersVaccinationChAdOx1CoronaVacCOVID-19VaccineMultiple factorsResponsePlaceboDoseTrialsAntibodies